Flagship Journal

Welcome to our third issue of the EMJ flagship for 2023, which focuses on rare diseases. Our team attended the European Conference on Rare Diseases (ECRD) at the end of June, and we are delighted to bring you the highlights from the event. The ECRD saw patients, clinicians, policy makers, and other key stakeholders come together to enable innovation and help drive rare disease policies across Europe.

This issue shares insightful reviews, research articles, and case studies from across medical disciplines…

Welcome to our first flagship EMJ journal of the year that has a mini-focus on COVID-19, sharing case studies alongside our article…

Email subject line: Homozygous familial hypercholesterolaemia and biomarkers for COVID-19 in EMJ 6.4Introduction…

Our third flagship journal of 2021 contains peer-reviewed, expert research articles sharing the most recent scientific advancements and innovations from a range of disciplines including hepatology, gastroenterology, microbiology, and much more. The articles contain up-to-date and significant coverage relevant to many specialities and are accompanied by interviews with world class experts.

The second flagship journal of 2021 comprises a selection of articles highlighting key advances across a range of therapeutic disciplines including haematology, rheumatology, respiratory medicine, and more. Themes covered in this issue appeal to a broad range of healthcare professionals and include COVID-19, acute myeloid leukaemia, and Ehlers-Danlos Syndrome, among others.

EMJ 6.1 brings together peer-reviewed research articles sharing topical advancements across a range of therapeutic disciplines, including cardiology, gastroenterology, microbiology, and more. These are accompanied by exciting features as well as interviews with world-class experts in dermatology and oncology, making this an issue that will cater to every clinician.

In this supplement to EMJ, two symposia that delivered the fundamental aspects and crucial considerations of the diagnosis and…